Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MabVax Therapeutics Inc.

Division of MabVax Therapeutics Holdings Inc.
www.mabvax.com

Latest From MabVax Therapeutics Inc.

Deal Watch: Gilead Moves Into Kidney Disease Via Goldfinch Collaboration

Goldfinch’s Kidney Genome Atlas may yield novel therapies for diabetic kidney disease and orphan renal indications, with Gilead holding option rights. Spectrum licenses IP from ImmunGene that could safely harness the potential of interferon therapy in cancer.

Deals Business Strategies

Deal Watch: Sanofi Retains Options To Two Bispecifics While Exiting Antibody Pact With Regeneron

Sanofi and Regeneron terminate the immuno-oncology partnership signed in 2015, but will continue to collaborate on Libtayo. Biogen signs a pair of partnerships in CNS disorders, with C4 and Skyhawk, and more deals from the first day of the J.P. Morgan conference.

Business Strategies Commercial

Neuroblastoma Genomic Discovery Gateway To Potential Therapies

Scientists at NEO New Oncology AG and the University of Cologne have identified previously unknown genomic alterations in neuroblastoma which may help improve tumor diagnostics and potentially leading to the development of new therapies for the pediatric disease.

Cancer

Deal Watch: Seattle Genetics And Genmab Partner Again On Anti-Cancer ADC

MabVax to provide antibody-targeting technology to Memorial Sloan-Kettering, which could yield CAR-T therapeutic candidates for which Juno Therapeutics will hold an exclusive option. Mylan acquires injectable anticoagulant Arixtra from Aspen for $300 million, while Asterias will work with Cancer Research UK on non-small cell lung cancer program.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • MabVax Therapeutics Holdings Inc.
  • Senior Management
  • David Hansen, Pres. & CEO
    Gregory P Hanson, CFO
    Philip Livingston, MD, CSO
  • Contact Info
  • MabVax Therapeutics Inc.
    Phone: (858) 259-9405
    11588 Sorrento Valley Rd.
    Ste. 20
    San Diego, CA 92121
    USA
UsernamePublicRestriction

Register